November 27, 2007

BioSyntech Awarded 2007 Innovation Award from ADRIQ

LAVAL, Quebec — November 27, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced it has been awarded the 2007 Innovation Award in the “Partnership” category by the Association de la Recherche Industrielle du Quebec (ADRIQ) for its successful partnership with the École Polytechnique de Montréal (École Polytechnique).   More

November 12, 2007

Biosyntech Announces Second Quarter 2008 Financial Results

LAVAL, Quebec — November 12, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced its financial results for the three and six-month periods ended September 30, 2007.   More

August 13, 2007

BioSyntech announces first quarter 2008 financial results

LAVAL, Quebec, Canada — August 13, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced financial results for the first quarter ended June 30, 2007.   More

July 11, 2007

Biosyntech appoints new vice president, regulatory affairs and quality

LAVAL, Quebec, Canada — July 11, 2007 —- BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today announced that Mrs. Flor del Pilar Arana has been appointed Vice President, Regulatory Affairs and Quality.   More

June 29, 2007

BioSyntech announces fourth quarter and 2007 year-end financial results

LAVAL, Quebec, Canada — June 29, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today announced financial results for the fourth quarter and fiscal year ended March 31, 2007.   More

June 14, 2007

BioSyntech reaches significant BST-CarGel® clinical milestone

LAVAL, Quebec, Canada — June 14, 2007 — BioSyntech Inc. (TSX: BSY) announced today that it has completed the enrolment of a 20 patient subset of its ongoing Canadian-European BST-CarGel® pivotal trial. The data collected from these patients will be submitted to the U.S. Food and Drug Administration as a pilot study in support of an Investigational Device Exemption (IDE) for a US pivotal trial.   More

April 02, 2007

BioSyntech announces refinancing of loan

LAVAL, Québec, Canada —April 2, 2007 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX: BSY) today announced that it has entered into a formal agreement with the Business Development Bank of Canada (the “BDC”), to refinance part of their loan of $2,500,000 by way of conventional mortgage.   More

February 14, 2007

BioSyntech reports its third quarter results

LAVAL, Québec, Canada — February 14, 2007 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2006.   More

February 08, 2007

BioSyntech announces start of patient recruitment into BST-DermOnTM pivotal clinical trial

LAVAL, Quebec, Canada — February 8, 2007 — BioSyntech Inc. (TSX: BSY) announced today the start of recruitment into its Canadian pivotal clinical trial for BST-DermOnTM, a medical device designed to repair chronic wounds and based on the natural polysaccharide chitosan. Dr. Gary Sibbald, an internationally recognized leader in the field of dermatology and wound repair, is the Principal Investigator for this trial.   More

December 04, 2006

Monday, December 4 - BioSyntech, Inc. Opens the Markets

Claude LeDuc, CEO of BioSyntech, Inc., opened the markets today. BioSyntech is a biotechnology company specializing in the discovery, development, and manufacturing of innovative, cost-effective, and physician-friendly therapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech trades on TSX under the stock symbol BSY.    More

November 29, 2006

BioSyntech reports second quarter results

LAVAL, Québec, Canada — November 29, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX: BSY) today reported its results for the second quarter and six-month period ended September 30, 2006.   More

November 20, 2006

BioSyntech signs scientific collaboration agreement with Nicholas Piramal

Laval, Quebec, Canada — November 20, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX:BSY) is pleased to announce the signing of a scientific collaboration between the Company and their biopharmaceutical partner Nicholas Piramal.   More

October 30, 2006

BioSyntech shares begins trading on the TSX today

LAVAL, Québec, Canada — October 30, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") at the open of trading today, Monday October 30, 2006 under the symbol “BSY”.   More

October 11, 2006

BioSyntech Receives Notice of Allowance from the US Patent and Trademark Office on Key BST-CarGel® Patent

LAVAL, Québec, Canada — October 11, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, “Composition and method for the repair and regeneration of cartilage and other tissues”. BST CarGel®, the Company's lead product,   More

September 29, 2006

BioSyntech announces conditional approval for listing on the Toronto Stock Exchange

LAVAL, Québec, Canada — September 29, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce that its application to graduate to the Toronto Stock Exchange has been approved, subject only to the filing of final documentation.   More

September 25, 2006

Annual meeting of stockholders of BioSyntech, Inc.

LAVAL, QUEBEC, September 25, 2006 – Mr. Joseph Benarrosh, Chairman of the Board announces the Annual Meeting of Stockholders of BioSyntech, Inc.   More

August 25, 2006

BioSyntech reports first quarter results

LAVAL, Québec, Canada — August 25, 2006 — BioSyntech, Inc. ("BioSyntech" or "the Company") (TSX-V: BSY) today reported its results for the first quarter ended June 30, 2006.   More

August 24, 2006

BioSyntech receives approval for Canadian BST-DermOn® pivotal clinical trial

LAVAL, Quebec, Canada — August 24, 2006 — BioSyntech Inc. (TSX-V: BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin enrolling subjects in its pivotal clinical trial for BST-DermOn®, a medical device designed to repair chronic wounds.   More

August 08, 2006

BioSyntech strengthens management team with key appointments. Company names François Michaud as chief financial officer and Richard Lacombe as vice-president clinical affairs

LAVAL, Québec, Canada — August 8, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) is pleased to announce the appointments of Mr. François Michaud C.A., C.M.A., as Chief Financial Officer and Mr. Richard Lacombe Ph.D., M.B.A., as Vice-President Clinical Affairs of the Company.   More

July 28, 2006

BioSyntech reports major progress in fiscal 2006 Strengthens balance sheet with $28 million financing Enhances board with additional members

LAVAL, Québec, Canada — July 28, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for the fiscal year ended March 31, 2006.   More

June 13, 2006

BioSyntech strengthens board with new member

LAVAL, Québec, Canada — June 13, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Dr. Joyce Tsang to its Board of Directors. Dr. Tsang is the representative for ProQuest Investments, which invested in the Company’s recent financing.   More

May 25, 2006

BioSyntech appoints new board member

LAVAL, Québec, Canada — May 25, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today announced the appointment of Rudy Huber to its board of directors. Mr. Huber is the representative for an institution that invested in the Company’s recent financing.   More

May 10, 2006

BioSyntech grants stock options

LAVAL, Quebec, Canada – May 9, 2006 – In accordance with its continuous disclosure obligations, BioSyntech, Inc. (TSX-V: BSY) announces the grant of options to acquire 50,000 common shares of its capital stock at a price of $0.49 per share for a period of five years to a Board Director.   More

May 03, 2006

BioSyntech closes its private placement for a total of $21 Million with a $3 Million third and final tranche

LAVAL, Quebec, Canada – May 3rd, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the closing of the third tranche of its previously-announced financing. This final tranche involved the issuance of 7,125,000 Units at $0.42 per Unit for a total of $2,996,700. This brings the total financing to $21 million for the issuance of 50,000,000 Units. Each Unit consisted of one common share and half a warrant. Each full warrant entitles the holder to purchase one share at $0.65 prior to March 31, 2009.   More

April 18, 2006

BioSyntech closes $8 Million second tranche of its private placement and increases total offering to $21,7 Million

LAVAL, Quebec, Canada – April 17, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has increased the size of its previously announced private placement to $21,700,000, representing an aggregate of 51,666,666 units, at a price of $0.42 per unit, to accommodate the subscription of two strategic investors.   More

March 31, 2006

BIOSYNTECH, INC. ANNOUNCES FIRST CLOSING OF ITS PRIVATE PLACEMENT FOR AN AMOUNT OF $10 MILLION

LAVAL, Quebec, Canada – March 31, 2006 – BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today a first closing of its private placement involving the issuance of 23,810,000 units at a price of $0.42 per unit for gross proceeds of $10,000,200. Each unit consists of one common share of the Company and one half of one warrant. Each warrant entitles the holder to purchase, for a period of three years, one common share at a price of $0.65 per share.   More

March 20, 2006

BioSyntech Inc. announces new closing date for its private placement, continuation under the Canada Business Corporations Act and appointment of new chairman

LAVAL, Quebec, Canada – March 20, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today the appointment of Joseph Benarrosh as Chairman of its board of directors, following the resignation of Amine Selmani, who remains as a board member. Mr. Benarrosh has been a board member of the Company since 2004.   More

February 28, 2006

BioSyntech Inc. announces proposed private placement

LAVAL, Quebec, Canada – February 28, 2006 – BioSyntech Inc. (“BioSyntech” or the “Company”) (TSX V: BSY) announced today that it has retained the services of Desjardins Securities Inc. as lead agent and Dundee Securities Corporation (together, the “Agents”) for a private placement of 23,810,000 units of the Company at a price of $0.42 per unit, for gross proceeds of $10,000,200.   More

February 24, 2006

BioSyntech reports its third quarter results

LAVAL, Québec, Canada — February 24, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX V: BSY) today reported its results for its third quarter and nine-month period ended December 31, 2005. Highlights and subsequent events:   More

February 16, 2006

BioSyntech announces extension of BDC loan

LAVAL, Quebec, Canada — February 16, 2006 — BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) today announced that it has negotiated the extension until February 15, 2009 of the $2,500,000 loan obtained in 2002 from the Business Development Bank of Canada (the “BDC”), on the same terms and conditions. All outstanding interest due on the initial loan, which had been capitalized since disbursement, was paid.   More

February 09, 2006

BioSyntech closes transaction with Kuhnil Pharma Co. LTD

LAVAL, Quebec, Canada — February 9, 2006 — BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX-V: BSY) today announced the closing of the transaction with Kuhnil Pharma Co. Ltd (“Kuhnil”), one of Korea's leading pharmaceutical companies, pursuant to which Kuhnil purchased 1,500,000 common shares of the Company at a price of $0.80 per share, for total proceeds of $1.2 million.   More

January 09, 2006

BioSyntech's BST-CarGel subject of prestigious publication

LAVA